To direct the Secretary of Health and Human Services to establish a Lung Cancer Task Force, and for other purposes.

Bill ID: 119/hr/6319
Last Updated: November 28, 2025

Sponsored by

Rep. Gottheimer, Josh [D-NJ-5]

ID: G000583

Follow the money

The bill

To direct the Secretary of Health and Human Services to establish a Lung Cancer Task Force, and for other purposes.

HR. 6319, 119th Congress β€” read as touching Hospitals & Health Systems.

The sponsor

Rep. Gottheimer, Josh [D-NJ-5]

Every bill has someone who introduced it. That name is where the paper trail starts.

The money

$193,281 raised

29 itemised contributions to this sponsor, pulled from FEC filings.

Bill's Journey to Becoming a Law

Track this bill's progress through the legislative process

Latest Action

Invalid Date

Introduced

πŸ“ Current Status

Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.

πŸ›οΈ

Committee Review

πŸ—³οΈ

Floor Action

βœ…

Passed Senate

πŸ›οΈ

House Review

πŸŽ‰

Passed Congress

πŸ–ŠοΈ

Presidential Action

βš–οΈ

Became Law

πŸ“š How does a bill become a law?

1. Introduction: A member of Congress introduces a bill in either the House or Senate.

2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.

3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.

4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.

5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.

6. Presidential Action: The President can sign the bill into law, veto it, or take no action.

7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!

Bill Summary

No summary available

πŸ’° Campaign Finance Network

Rep. Gottheimer, Josh [D-NJ-5]

Congress 119 β€’ 2024 Election Cycle

Total Contributions
$193,281
21 donors
PACs
$0
Organizations
$63,374
Committees
$0
Individuals
$129,907

No PAC contributions found

1
AMERICAN EXPRESS
2 transactions
$33,562
2
PAYROLL DATA PROCESSING
4 transactions
$24,762
3
EASTERN BAND OF CHEROKEE INDIANS
1 transaction
$3,300
4
SEKAS LAW GROUP LLC
1 transaction
$1,500
5
SANDOR F. GENET & ASSOCIATES, P.A.
1 transaction
$250

No committee contributions found

1
FIRESTONE MILKEN, SARAH
2 transactions
$23,100
2
WEBB, DAN K.
2 transactions
$13,200
3
MCKNIGHT, ANDREW
2 transactions
$10,000
4
CRETELLA, JEANNE
2 transactions
$10,000
5
WOODSIDE, KEVIN E.
1 transaction
$6,600
6
CARSON, RUSSELL L.
1 transaction
$6,600
7
ROSMAN, ELIZABETH
1 transaction
$6,600
8
BOECKMANN, ALAN
1 transaction
$6,600
9
MCLEAN, TERRENCE
1 transaction
$6,600
10
MANN, TRACY
1 transaction
$6,600
11
REYNOLDS, RALPH
1 transaction
$6,600
12
HANOVER, ADAM
1 transaction
$6,600
13
ROBERTSON, WILHELMINA E.
1 transaction
$5,807
14
VIXAMAR, STEVE
1 transaction
$5,000
15
KNIGHTS, CLIFFORD
1 transaction
$5,000
16
CUBERO, MARIA
1 transaction
$5,000

Donor Network - Rep. Gottheimer, Josh [D-NJ-5]

PACs
Organizations
Individuals
Politicians

Hub layout: Politicians in center, donors arranged by type in rings around them.

Loading...

Showing 52 nodes and 29 connections (60 secondary connections hidden)

Total contributions: $193,281

Top Donors - Rep. Gottheimer, Josh [D-NJ-5]

Showing top 21 donors by contribution amount

5 Orgs16 Individuals

Industry Impact

Which industries are materially affected by specific provisions in this bill. 3 helped.

  • Section 2(c)(1) directs the task force to examine disparities in lung cancer research, funding, and patient access to treatments, which could lead to recommendations that increase funding or improve access, benefiting hospitals and health systems that provide lung cancer care.

  • +Medical Devicesconfidence 0.70

    Section 2(c)(3) focuses on lung cancer screenings in the United States; increased screening could drive demand for diagnostic imaging devices (e.g., CT scanners) used in lung cancer detection, benefiting medical device manufacturers.

  • +Pharmaceuticalsconfidence 0.70

    Section 2(d) includes recommendations for increasing Federal funding for lung cancer research, which could support drug development and clinical trials, benefiting pharmaceutical companies involved in lung cancer therapeutics.

Who funds the sponsor on these industries

For each industry this bill affects, here's what the sponsor (Rep. Gottheimer, Josh [D-NJ-5])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent β€” they are a record of who funds the people writing the law.

Industries this bill HELPS

Related Bills